Japan
· Delayed Price · Currency is JPY Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of JPY 355.57 billion. The enterprise value is 646.70 billion.
| Market Cap | 355.57B |
| Enterprise Value | 646.70B |
Important Dates
The next estimated earnings date is Thursday, July 31, 2025.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Sumitomo Pharma has 397.29 million shares outstanding.
| Current Share Class | 397.29M |
| Shares Outstanding | 397.29M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 17.05% |
| Float | 180.16M |
Valuation Ratios
The trailing PE ratio is 15.05 and the forward PE ratio is 7.48. Sumitomo Pharma's PEG ratio is 0.73.
| PE Ratio | 15.05 |
| Forward PE | 7.48 |
| PS Ratio | 0.89 |
| PB Ratio | 2.10 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 44.44 |
| P/OCF Ratio | 21.55 |
| PEG Ratio | 0.73 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.16, with an EV/FCF ratio of 80.82.
| EV / Earnings | 27.36 |
| EV / Sales | 1.62 |
| EV / EBITDA | 17.16 |
| EV / EBIT | 53.37 |
| EV / FCF | 80.82 |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 1.85.
| Current Ratio | 1.07 |
| Quick Ratio | 0.43 |
| Debt / Equity | 1.85 |
| Debt / EBITDA | 8.14 |
| Debt / FCF | 39.27 |
| Interest Coverage | 2.09 |
Financial Efficiency
Return on equity (ROE) is 14.52% and return on invested capital (ROIC) is 1.52%.
| Return on Equity (ROE) | 14.52% |
| Return on Assets (ROA) | 0.99% |
| Return on Invested Capital (ROIC) | 1.52% |
| Return on Capital Employed (ROCE) | 2.58% |
| Revenue Per Employee | 104.08M |
| Profits Per Employee | 6.17M |
| Employee Count | 4,980 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.46 |
Taxes
| Income Tax | -6.02B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +134.91% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +134.91% |
| 50-Day Moving Average | 870.14 |
| 200-Day Moving Average | 689.38 |
| Relative Strength Index (RSI) | 47.62 |
| Average Volume (20 Days) | 9,948,130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of JPY 398.83 billion and earned 23.63 billion in profits. Earnings per share was 59.49.
| Revenue | 398.83B |
| Gross Profit | 245.40B |
| Operating Income | 13.02B |
| Pretax Income | 17.61B |
| Net Income | 23.63B |
| EBITDA | 38.59B |
| EBIT | 13.02B |
| Earnings Per Share (EPS) | 59.49 |
Balance Sheet
The company has 23.12 billion in cash and 314.25 billion in debt, giving a net cash position of -291.13 billion or -732.79 per share.
| Cash & Cash Equivalents | 23.12B |
| Total Debt | 314.25B |
| Net Cash | -291.13B |
| Net Cash Per Share | -732.79 |
| Equity (Book Value) | 169.48B |
| Book Value Per Share | 426.59 |
| Working Capital | 16.03B |
Cash Flow
In the last 12 months, operating cash flow was 16.50 billion and capital expenditures -8.50 billion, giving a free cash flow of 8.00 billion.
| Operating Cash Flow | 16.50B |
| Capital Expenditures | -8.50B |
| Free Cash Flow | 8.00B |
| FCF Per Share | 20.14 |
Margins
Gross margin is 61.53%, with operating and profit margins of 3.27% and 5.93%.
| Gross Margin | 61.53% |
| Operating Margin | 3.27% |
| Pretax Margin | 4.42% |
| Profit Margin | 5.93% |
| EBITDA Margin | 9.67% |
| EBIT Margin | 3.27% |
| FCF Margin | 2.01% |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.01% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 6.65% |
| FCF Yield | 2.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of 0.93 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.93 |
| Piotroski F-Score | 6 |